Longwood Capital Partners LLC Has Boosted Its Assembly Biosciences INC (ASMB) Holding by $39.27 Million

October 11, 2018 - By Peter Erickson

Longwood Capital Partners Llc increased its stake in Assembly Biosciences Inc (ASMB) by 649.68% based on its latest 2018Q2 regulatory filing with the SEC. Longwood Capital Partners Llc bought 1.01M shares as the company’s stock declined 23.00% while stock markets rallied. The institutional investor held 1.16M shares of the health care company at the end of 2018Q2, valued at $45.56M, up from 155,000 at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Assembly Biosciences Inc for a number of months, seems to be bullish on the $633.24 million market cap company. The stock increased 0.55% or $0.135 during the last trading session, reaching $24.885. About 42,918 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 26.62% since October 11, 2017 and is uptrending. It has outperformed by 11.00% the S&P500.

Longwood Capital Partners Llc, which manages about $561.75 million US Long portfolio, decreased its stake in Spdr Series Trust (Put) (XBI) by 400,000 shares to 100,000 shares, valued at $9.52 million in 2018Q2, according to the filing. It also reduced its holding in Catalyst Biosciences Inc by 324,722 shares in the quarter, leaving it with 830,000 shares, and cut its stake in Veracyte Inc (NASDAQ:VCYT).

More notable recent Assembly Biosciences, Inc. (NASDAQ:ASMB) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares” on October 10, 2018, also Benzinga.com with their article: “Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade” published on October 08, 2018, Benzinga.com published: “32 Stocks Moving In Thursday’s Mid-Day Session” on October 04, 2018. More interesting news about Assembly Biosciences, Inc. (NASDAQ:ASMB) were released by: Benzinga.com and their article: “45 Biggest Movers From Yesterday” published on October 05, 2018 as well as Globenewswire.com‘s news article titled: “Assembly Biosciences Announces Oral Presentation at 2018 AASLD” with publication date: October 02, 2018.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Coverage

Among 4 analysts covering Assembly Biosciences (NASDAQ:ASMB), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Assembly Biosciences had 6 analyst reports since April 13, 2018 according to SRatingsIntel. The rating was maintained by FBR Capital on Tuesday, May 8 with “Neutral”. FBR Capital maintained the shares of ASMB in report on Thursday, June 21 with “Hold” rating. Chardan Capital Markets downgraded the stock to “Neutral” rating in Friday, April 13 report. The stock of Assembly Biosciences, Inc. (NASDAQ:ASMB) has “Buy” rating given on Monday, October 8 by FBR Capital.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>